Goldman Jonathan
SEC CIK 2013869 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | Dir | 3,166 | — | $163.0K | 4 | 2025-03-28 | 2026-03-28 |
Most active insiders at AVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Sullivan Christopher Ryan | CFO | — | $3.72M |
| 2 | Doyle Mittie | Chief Medical Off | — | $2.98M |
| 3 | VARKI PAUL | CLO | — | $1.51M |
| 4 | Goldman Jonathan | Dir | — | $163.0K |
| 5 | Chan Mitchell | Dir | — | $72.5K |
| 6 | Riley Jennifer | Chief Strategy Off | — | $52.0K |
| 7 | Truex Samantha | Dir | — | — |
| 8 | KANTOFF AARON | Dir | — | — |
| 9 | NEIL GARRY ARTHUR | CEO, Dir | — | — |
| 10 | KAPLAN GILLA | Dir | — | — |
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-31 | 2026-03-28 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Dir | M - OptEx | — | +3,166 | 3,166 | New | — |
| DM | 2025-11-17 | 2025-11-14 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Dir | S - Sale+OE | $14.34 | -11.4K | 0 | -100% | -$163.0K |
| D | 2025-11-17 | 2025-11-14 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Dir | M - OptEx | $9.88 | +8,200 | 8,200 | New | +$81.0K |
| D | 2025-04-01 | 2025-03-28 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Dir | M - OptEx | — | +3,167 | 3,167 | New | — |
Purchase Sale Sale after option exercise All abbreviations